Keyword: Moodys Investors Service

Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with multiple challenges.

The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.